ArticleBalkan medical journal2025
Epidemiology of Parvovirus B19 in Türkiye: A Descriptive Analysis of National Surveillance Data (2020-2024).
Article in Balkan medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Parvovirus B19 (B19V) infection occurs worldwide seasonally, especially in school-age children. Due to limited surveillance, clinicians report an increase of cases to identify outbreaks, while labs determine seropositivity rates. In 2024, B19V outbreak occurred in Türkiye and many other countries. Aims: To estimate incidences of B19V infection in Türkiye from 2020 to 2024 using National Infectious Disease Surveillance and Early Warning System (IZCI) and to determine case fatality rate (CFR) during the 2024 outbreak period. Study Design: Retrospective descriptive study. Methods: The number of cases was obtained from the syndromic surveillance of rash diseases in national database. All notifications with International Classification of Diseases, 10th Revision diagnosis code "erythema infectiosum" within the syndromic surveillance were included in the study. All age groups were included in the study and no specific group was excluded. Annual estimated incidences were calculated for past 5 years. The distribution of cumulative incidence for the outbreak by age group and geographical regions was analysed. CFR was calculated for the outbreak period by using the proportion of people who have been diagnosed with B19V. Disease indicators were calculated as crude rates. Results: The estimated incidence in 2024 was 15.24 per 100,000. The peak of the outbreak was in May. The regions with the highest cumulative incidences during the outbreak period were the Black Sea, Marmara, and Central Anatolia. The highest cumulative incidence was 102.64 per 100,000 in 5-9 age group. The CFR was calculated as 0.0184% in the outbreak with 2 deaths out of 10,898 cases. Conclusion: Türkiye has experienced the largest B19V outbreak between February and June 2024. This study showed the unusual scale of B19V post-pandemic, suggesting that such outbreaks can be expected after pandemics. The establishment of syndromic surveillance has proved critical for early outbreak detection and response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.